# CancerCare Manitoba

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/cancercare-manitoba/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 67.2 |
| Citations | 365,993 |
| City | Winnipeg |
| Country | CA |
| Description | CancerCare Manitoba is a research organisation in Winnipeg, CA. OpenAlex records 4,289 works and 365,993 citations for it. 767 researchers list it as their most recent affiliation. |
| Homepage | https://www.cancercare.mb.ca |
| OpenAlex ID | https://openalex.org/I4210088414 |
| Region | Manitoba |
| Researchers | 767 |
| ROR ID | https://ror.org/005cmms77 |
| Type | healthcare |
| Wikidata ID | Q30282110 |
| Works | 4,289 |

## University papers

- [The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups](https://scholariq.org/papers/the-genomic-and-transcriptomic-architecture-of-2-000-breast-tumours-reveals/)
- [Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-after-adjuvant-chemotherapy-in-her2-positive-breast-cancer/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapes](https://scholariq.org/papers/the-somatic-mutation-profiles-of-2-433-breast-cancers-refine-their-genomic-and/)
- [Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort](https://scholariq.org/papers/neoadjuvant-chemotherapy-with-trastuzumab-followed-by-adjuvant-trastuzumab/)
- [A complex containing N-CoR, mSln3 and histone deacetylase mediates transcriptional repression](https://scholariq.org/papers/a-complex-containing-n-cor-msln3-and-histone-deacetylase-mediates/)
- [Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups](https://scholariq.org/papers/dynamics-of-breast-cancer-relapse-reveal-late-recurring-er-positive-genomic/)
- [Low bone mineral density and fracture burden in postmenopausal women](https://scholariq.org/papers/low-bone-mineral-density-and-fracture-burden-in-postmenopausal-women/)

## University top topics

Showing 8 of 25.

- [Advanced Radiotherapy Techniques](https://scholariq.org/topics/advanced-radiotherapy-techniques/)
- [Global Cancer Incidence and Screening](https://scholariq.org/topics/global-cancer-incidence-and-screening/)
- [Palliative Care and End-of-Life Issues](https://scholariq.org/topics/palliative-care-and-end-of-life-issues/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Hematopoietic Stem Cell Transplantation](https://scholariq.org/topics/hematopoietic-stem-cell-transplantation/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)
- [Childhood Cancer Survivors' Quality of Life](https://scholariq.org/topics/childhood-cancer-survivors-quality-of-life/)
- [Acute Lymphoblastic Leukemia research](https://scholariq.org/topics/acute-lymphoblastic-leukemia-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.